Announcements
Midatech Pharma PLC : Midatech announces positive Q-Octreotide data
RNS Number : 2857W
Midatech Pharma PLC
26 April 2016
Midatech Pharma PLC
("Midatech" or the "Company")
Midatech Pharma announces positive pharmacokinetic data with Q-Octreotide
~ Release profile of Midatech's Q-Octreotide compared favourably with the reference product and current market leader ~
Midatech Pharma (AIM: MTPH; Nasdaq: M
Galileo Resources : Silverton Project Farm-Out
RNS Number : 9542V
Galileo Resources PLC
21 April 2016
For immediate release: 14.00
21 April 2016
Galileo Resources Plc
("Galileo" or "the Company")
GALILEO EXECUTES EXCLUSIVE AGREEMENT FOR FARM-OUT OF THE COMPANY'S SILVERTON GOLD PROPERTY IN NEVADA USA
Galileo is pleased to announce that it has executed a
Oxford Pharmascience : Positive Regulatory Advice from MHRA
RNS Number : 5992V
Oxford Pharmascience Group PLC
19 April 2016
Oxford Pharmascience Group plc
("Oxford Pharmascience" or "the Company")
Oxford Pharmascience Announces Positive Regulatory Advice from MHRA on OXPzeroTM NSAIDs programme
Oxford Pharmascience, the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, announces that it has received cl
Epistem Holdings plc : Epistem Begins Full Commercial Launch of Genedrive
RNS Number : 4486V
Epistem Holdings plc
18 April 2016
RNS Press Release
For release: 18 April 2016
Epistem Begins Full Commercial Launch for Genedrive® Tuberculosis Tests in India
Genedrive® Enables Early Detection of TB and Antibiotic Resistance Without Need for Central Laboratory Facilities
Epistem Holdings Plc (LSE: EHP), the mol
Vela Technologies : Completion of investment in Portr Limited
RNS Number : 2831V
Vela Technologies PLC
15 April 2016
15 April 2016
Vela Technologies plc
("Vela" or the "Company")
Completion of investment in Portr Limited
Further to the announcement of 8 March 2016 the Board of Vela (AIM: VELA), the investing company focused on early stage and pre-IPO disruptive technology investments, is pleased to announce that Ve
Neville Registrars welcomes Osirium Technologies plc
Neville Registrars is delighted to welcome Osirium Technologies plc as the newest addtion to its list of client companies.
The Osirium team have intelligently combined the latest generation of Cyber-Security and Automation technology to create the world’s first, built-for-purpose, Privileged Protection and Task Automation solution for the Hybrid-Cloud world.
Further information can be found on the Company's website: CONTINUE READING
Flowgroup plc : First commercial Flow boiler installs complete
RNS Number : 2600V
Flowgroup plc
14 April 2016
Flowgroup plc
("Flowgroup" or the "Company")
First commercial installations of Flow boiler now complete
Flowgroup plc (AIM: FLOW), which provides innovative energy technologies, energy supply and energy services, announces that the first commercial installs of the Flow boiler in customer homes have be
Midatech Pharma PLC : Commercial Launch of Zuplenz? (Ondansetron) in US
RNS Number : 7173U
Midatech Pharma PLC
11 April 2016
Midatech Pharma PLC
("Midatech" or the "Company")
Midatech's Commercial Launch of Zuplenz® (Ondansetron) Oral Soluble Film to Prevent Post-Operative, Chemotherapy and Radiation-Induced Nausea and Vomiting in US
- Midatech further expands its co
Fitbug Holdings PLC : Successful Customer Rollout With Strategic Partner
RNS Number : 8032S
Fitbug Holdings PLC
22 March 2016
Fitbug Holdings Plc / Epic: FITB.L / Index: AIM / Sector: Leisure
22 March 2016
FITBUG HOLDINGS PLC ('FITBUG' OR 'THE COMPANY')
SUCCESSFUL CUSTOMER ROLLOUT WITH STRATEGIC PARTNER PUNTER SOUTHALL
Fitbug Holdings, the AIM quoted technology developer and digital wellness pioneer, is pleased to announce the success of an initi
Epistem Holdings plc : Funding award from US Department of Defense
RNS Number : 6988S
Epistem Holdings plc
21 March 2016
RNS Press Release
For release: 21 March 2016
Award of Funding for Next Stage of US Department of Defense Programme
to Develop Genedrive® Biohazard Identification Tests
Epistem Holdings Plc (LSE: EHP), the molecular diagnostics, personalised medicine and biotechnology company, announces today that the US Departm
